Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,911 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06630611RecruitingPhase 2
A new immune cell therapy for melanoma, lung, and cervical cancer
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
BarcelonaAges 18 years+ - NCT06001151RecruitingPhase 2
Cadonilimab plus chemo for PD-L1 negative lung cancer
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
Wuhan, HubeiAges 18–75 - NCT06907095Recruiting
Early cancer detection study for high-risk individuals
This study tests if a simple blood or fluid test can find cancer early in people with a higher-than-average risk. If you have certain genetic mutations, a strong family history of cancer, or other high-risk conditions, you may be able to join.
VillejuifAges 18 years+ - NCT05986318RecruitingPhase 2
Reducing breathing issues from lung radiation in people with ILD
This trial tests whether a combination of two medications (dexamethasone and N-acetyl cysteine) can reduce breathing problems caused by radiation to lung tumors in patients who have both lung cancer and fibrotic interstitial lung disease (ILD). It aims to find a better way to manage side effects from radiation.
Vancouver, British ColumbiaAges 18 years+ - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT05875870Recruiting
Bright light and exercise program for lung or esophageal cancer
This trial tests whether a structured bright-light exposure routine combined with a specific exercise program can help people with newly diagnosed lung or esophageal cancer. You may be eligible if you’re in early-to-middle cancer stages and able to safely participate in walking-based activities.
Taipei City, TaipeiAges 20 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT03987633Recruiting
Study links health records and samples to understand health gaps
This study asks people affected by a specific illness (or their family member) to share saliva (and sometimes blood) and answer health and quality-of-life questions. The goal is to better understand and reduce health inequality by matching new information with medical records.
Wolverhampton, West MidlandsAges 6 years+ - NCT06332131Enrolling by invitation
Heart blood vessel effects of immunotherapy in breast and lung cancer
This trial studies whether immunotherapy drugs (called immune checkpoint inhibitors) affect the small blood vessels of the heart. If you have breast cancer or lung cancer and are starting a specific treatment plan, you may be asked to have a special heart scan before and during therapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05559645Recruiting
Oral drug trial for EGFR-mutated lung cancer after prior treatment
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Fort Smith, ArkansasAges 18 years+ - NCT07116057RecruitingPhase 1
CAR T cell therapy for FRa-positive cancers
This trial tests a new treatment called MOv19-BBz CAR T cells, which are specially designed immune cells that target a protein called FRa found on some cancer cells. It's for people with advanced lung cancer that has spread to the lining of the lung (malignant pleural effusion) and who have already tried at least one standard treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06403735RecruitingPhase 1
Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Guangzhou, GuangdongAges 18 years+ - NCT06987890Recruiting
Geriatric assessment for older adults with lung cancer getting SBRT
This study looks at how a geriatric assessment can help older adults with early-stage lung cancer who are getting a precise type of radiation therapy called SBRT. The goal is to understand their needs and improve care.
Boston, MassachusettsAges 65 years+ - NCT05482568RecruitingPhase 1/Phase 2
Study drug SHR-A1811 with two lung cancer medicines
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT06617936RecruitingPhase 2
Immunotherapy plus endostatin and chemo for stage III lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab), an anti-angiogenic drug (endostatin), and standard chemotherapy for people with stage III lung cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
Jinan, ShandongAges 18–75 - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT05978284RecruitingPhase 1/Phase 2
Study of ZG006 for small cell lung cancer or neuroendocrine carcinoma
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
Zhengzhou, HenanAges 18–75 - NCT06230445RecruitingPhase 3
Digital health app for lung cancer management
This trial tests a digital health app to help manage the entire treatment process for lung cancer. It may assist patients who are already undergoing or have completed treatments like surgery or chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,911 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.